<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="553">
  <stage>Registered</stage>
  <submitdate>6/04/2005</submitdate>
  <approvaldate>6/04/2005</approvaldate>
  <nctid>NCT00107627</nctid>
  <trial_identification>
    <studytitle>Skin Incision Study - Closure of Skin Incisions in Gynecological Cancer Surgery</studytitle>
    <scientifictitle>Skin Incision Study - Closure of Skin Incisions in Gynecological Cancer Surgery</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>SIS001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Other surgery</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Caprosyn subcuticular sutures.
Other interventions - Monocryl subcuticular sutures.
Other interventions - Skin staples;

Active Comparator: 1 - Skin staples;

Active Comparator: 2 - Monocryl subcuticular sutures.

Active Comparator: 3 - Caprosyn subcuticular sutures.


Other interventions: Caprosyn subcuticular sutures.
Caprosyn subcuticular sutures.

Other interventions: Monocryl subcuticular sutures.
Monocryl subcuticular sutures.

Other interventions: Skin staples;
Skin staples;

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Efficacy of the device as measured by cosmesis, pain and requirement for analgesic and antibiotic medication</outcome>
      <timepoint>6 weeks after surgery</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the wound healing process (normal or delayed), cosmesis and pain, requirement for surgical or medical intervention (analgesic and antibiotic medication)</outcome>
      <timepoint>3 months after surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety of the device as expressed in the incidence of adverse events following surgery</outcome>
      <timepoint>6 weeks after surgery</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Public patients at RBWH and at the Mater Public Hospital booked for elective surgery
             (laparotomy)

          -  Surgery for suspected or proven gynecological cancer

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Patient compliance and geographic proximity that allow adequate follow-up

          -  Signed written informed consent

          -  Females &gt;=18 years of age</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Unplanned laparotomy

          -  Laparoscopic procedures

          -  Unwillingness of the patient to participate in the trial

          -  Non-compliance of participant

          -  Unavailability for follow-up

          -  Patients who are unable or unwilling to give informed consent</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose />
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>90</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>QCGC, Royal Brisbane and Women's Hospital - Herston</hospital>
    <hospital>Mater Adult Public Hospital - South Brisbane</hospital>
    <postcode>4029 - Herston</postcode>
    <postcode>4101 - South Brisbane</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Queensland Centre for Gynaecological Cancer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The Skin Incision Study evaluates the efficacy of skin closure methods: skin staples and
      subcuticular sutures at 6 weeks and at 3 months following the operation by measuring cosmesis
      and pain.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00107627</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Andreas Obermair</name>
      <address>Queensland Centre for Gynaecological Cancer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>